

MEDICAL ASSISTANCE BULLETIN

ISSUE DATE

October 17, 2022

EFFECTIVE DATE

March 29, 2022

NUMBER

01-22-18, 05-22-07, 08-22-20, 09-22-17, 10-22-09, 24-22-12, 26-22-04, 30-22-11, 31-22-18, 33-22-16

SUBJECT

SARS-CoV-2 Vaccine Booster Manufactured by Moderna, Inc.

BY

Sally A. Kozak, Deputy Secretary

Office of Medical Assistance Programs

Sally G. Kozel

IMPORTANT REMINDER: All providers must revalidate the Medical Assistance (MA) enrollment of each service location every 5 years. Providers should log into PROMISe to check the revalidation dates of each service location and submit revalidation applications at least 60 days prior to the revalidation dates. Enrollment (revalidation) applications may be found at: https://www.dhs.pa.gov/providers/Providers/Pages/PROMISe-Enrollment.aspx.

PURPOSE:

The purpose of this bulletin is to inform Medical Assistance (MA) providers that the Department of Human Services (Department) added Current Procedural Terminology (CPT) code 0094A to the MA Program Fee Schedule for the administration of a booster dose of the novel coronavirus (SARS-CoV-2) vaccine manufactured by Moderna, Inc.

SCOPE:

This bulletin applies to all physicians, certified registered nurse practitioners, certified nurse midwives, physician assistants, outpatient hospital-based clinics, independent medical surgical clinics, federally qualified health centers, rural health clinics, home health agencies, ambulance providers, renal dialysis centers, psychiatric outpatient clinics, drug and alcohol outpatient clinics, and licensed pharmacies enrolled in the MA Program who may administer SARS-CoV-2 vaccines to MA beneficiaries in the Fee-for-Service (FFS) or managed care delivery systems. Providers rendering services in the MA managed care delivery system should address any coding and rate-related questions to the appropriate managed care organization.

BACKGROUND/DISCUSSION:

COMMENTS AND QUESTIONS REGARDING THIS BULLETIN SHOULD BE DIRECTED TO:

The appropriate toll-free number for your provider type.

Visit the Office of Medical Assistance Programs website at:

https://www.dhs.pa.gov/providers/Providers/Pages/Health%20Care%20for%20Providers/Contact-Information-for-Providers.aspx.

On March 29, 2022, the U.S. Food and Drug Administration amended the emergency use authorization for the Moderna, Inc. SARS-CoV-2 vaccine to allow for a booster dose of the vaccine. Additionally, the American Medical Association announced a new CPT code, 0094A, for the administration of a booster dose of the SARS-CoV-2 vaccine manufactured by Moderna, Inc. The code is distinct to the SARS-CoV-2 vaccine identified above. This level of specificity offers the ability to track each vaccine, even when the vaccine product is not reported, such as when the vaccine is available at no cost.

In response, the Department added CPT code 0094A to the MA Program Fee Schedule, which may be used for dates of service on and after March 29, 2022. This code is to be used by providers in both the FFS and managed care delivery systems to enable the Department to identify the specific SARS-CoV-2 vaccines that have been administered.

PROCEDURE:

Effective March 29, 2022, MA providers in both the FFS and managed care delivery systems are to bill for the administration of a booster dose of the SARS-CoV-2 vaccine manufactured by Moderna, Inc. to MA beneficiaries using the CPT code below.

Vaccine Manufacturer	Code	Code Description
Moderna, Inc.	0094A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage, booster dose

NOTE: Provider type 10, specialty100 (physician assistant) is included because physician assistants can be listed as the rendering provider pursuant to MA Bulletin 01-22-05, 08-22-05, 09-22-04, 10-22-01, 31-22-05, entitled "Billing Procedure Update for Certified Registered Nurse Practitioners and Physician Assistants."

https://www.dhs.pa.gov/docs/Publications/Documents/FORMS%20AND%20PUBS%20OMAP/MAB2022010701.pdf.

Attached is the "Addition to the Medical Assistance Program Fee Schedule: Procedure Code for the Administration of a Booster Dose of the SARS-CoV-2 Vaccine Manufactured by Moderna, Inc., Effective March 29, 2022". The attachment identifies the procedure code, national code description, provider type, provider specialty, place of service, pricing and/or informational modifiers if applicable, and MA fee for the procedure code for providers submitting MA FFS claims.

Federally Qualified Health Centers (FQHC) and Rural Health Clinics (RHC) are to bill with the applicable CPT codes above when a SARS-CoV-2 vaccine is administered to a MA beneficiary, including those administered to homebound beneficiaries, and no other services that constitute an encounter are rendered on that date. When the SARS-CoV-2 vaccine is administered during a billable encounter, FQHCs and RHCs are to bill procedure code T1015 to be paid their provider-specific Prospective Payment System rate, and the appropriate

SARS-CoV-2 vaccine CPT code on a separate claim line for tracking purposes, with no additional payment made for the administration of the vaccine. FQHCs and RHCs may not bill the Department for, or include on their cost report, SARS-CoV-2 vaccines they receive at no cost. FQHCs and RHCs may also not bill for the administration of the vaccine for which they will be paid by another entity to administer.

MA providers in both the FFS and managed care delivery systems who administer a booster dose of the SARS-CoV-2 vaccine to a MA beneficiary who is homebound should bill procedure code M0201 along with the applicable SARS-CoV-2 vaccine administration code. For additional information related to billing for the administration of SARS-CoV-2 vaccines to a MA beneficiary who is homebound, providers should refer to MA Bulletin 01-21-04, "SARS-CoV-2 Vaccine Administration for Beneficiaries who are Homebound" for billing instructions. The bulletin may be accessed at the link below:

https://www.dhs.pa.gov/docs/Publications/Documents/FORMS%20AND%20PUBS%20OMAP/MAB2021072901.pdf. For additional information related to FQHCs and RHCs billing for the administration of SARS-CoV-2 vaccines to an MA beneficiary who is homebound, providers should refer to MA Bulletin 08-20-68, "Federally Qualified Health Center and Rural Health Clinic Payment for SARS-CoV-2 Vaccine Administration" for billing instructions. The bulletin may be accessed at the link below:

https://www.dhs.pa.gov/docs/Publications/Documents/FORMS%20AND%20PUBS%20OMAP/MAB2022061001.pdf.

Providers may access the online version of the MA Program Fee Schedule on the Department's website at:

https://www.dhs.pa.gov/providers/Providers/Pages/Health%20Care%20for%20Providers/MA-Fee-Schedule.aspx.

For information on how licensed pharmacies enrolled in the MA Program who provide services to MA beneficiaries should bill for the administration of SARS-CoV-2 vaccines by a pharmacist, please refer to MA Bulletin 01-20-60, "SARS-CoV-2 Vaccine Administration by Pharmacists", issued December 30, 2020, at the link below:

 $\frac{https://www.dhs.pa.gov/docs/Publications/Documents/FORMS\%20AND\%20PUBS\%20OMAP/MAB2020123001.pdf.$

MA providers may also bill the MA Program for the vaccine for MA eligible beneficiaries by indicating, on the claim submission, the appropriate National Drug Code (NDC) and the units dispensed for the vaccine. Providers may access the DHS Pharmacy Services Covered Drugs Search Tool on the Department's website at:

https://www.humanservices.state.pa.us/CoveredDrugs/CoveredDrugs/Index.

Providers may not bill the Department for a SARS-CoV-2 vaccine they receive at no cost or for the administration of a SARS-CoV-2 vaccine for which they will be paid by another entity to administer.

Additional information and guidance pertaining to the SARS-CoV-2 vaccines can be found at the following links:

- American Medical Association https://www.ama-assn.org/practice-management/cpt/covid-19-cpt-coding-and-guidance.
- Centers for Disease Control and Prevention <u>https://www.cdc.gov/coronavirus/2019-ncov/vaccines/index.html.</u>
- Centers for Medicare & Medicaid Services
 https://www.medicaid.gov/resources-for-states/disaster-response-toolkit/coronavirus-disease-2019-covid-19/index.html.
- Pennsylvania Department of Health https://www.health.pa.gov/Pages/default.aspx.

ATTACHMENT:

Addition to the Medical Assistance Program Fee Schedule: Procedure Code for the Administration of a Booster Dose of the SARS-CoV-2 Vaccine Manufactured by Moderna, Inc., Effective March 29, 2022

Addition to the Medical Assistance Program Fee Schedule: Procedure Codes for the Administration of the Booster Dose of the SARS-CoV-2 Vaccine Manufactured by Moderna, Inc., Effective March 29, 2022

Procedure Code	National Code Description	Provider Type	Provider Specialty	Place of Service	Pricing Modifier	Informational Modifier	MA Fee	Prior Authorization Required	Limits
0094A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage, booster dose	01	183	12, 22			\$40.00	No	once per day
0094A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage, booster dose	05	050, 051	12, 99			\$40.00	No	once per day
0094A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage, booster dose	08	080	12, 31, 32, 50, 99			\$40.00	No	once per day
0094A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage, booster dose	08	081	12, 31, 32, 72, 99			\$40.00	No	once per day
0094A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage, booster dose	08	082	12, 49			\$40.00	No	once per day
0094A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage, booster dose	08	110	49			\$40.00	No	once per day

0094A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage, booster dose	08	184	12, 57		\$40.00	No	once per day
0094A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage, booster dose	09	All	11, 12, 31, 32, 99		\$40.00	No	once per day
0094A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage, booster dose	10	100	11, 12, 31, 32, 99		\$40.00	No	once per day
0094A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage, booster dose	24	All	11, 31, 32, 99		\$40.00	No	once per day
0094A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage, booster dose	24	240, 247	12		\$40.00	No	once per day
0094A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage, booster dose	26	260, 261	12, 99		\$40.00	No	once per day
0094A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage, booster dose	30	300	12, 65		\$40.00	No	once per day
0094A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage, booster dose	31	All	11, 12, 31, 32, 99		\$40.00	No	once per day

	Immunization administration by intramuscular injection of severe acute							
	respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease							
	[COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50							
0094A	mcg/0.5 mL dosage, booster dose	33	335	11, 12, 99		\$40.00	No	once per day